Extended Data Fig. 3: Inhibition of β-catenin signaling by WC522 and WC593.
From: Cholesterol-targeting Wnt–β-catenin signaling inhibitors for colorectal cancer
a. Inhibition of the active β-catenin level by WC522 and WC593 was measured in unstimulated APC-truncated CRC cells. GAPDH was employed as a gel loading control for all immunoblotting. Displayed gel images are representative of similar images from three independent measurements. b. Quantification of active β-catenin/GAPDH data shown in a. c. Inhibition of β-catenin transcriptional activity by WC522 and WC593 in unstimulated APC-truncated CRC cells measured by the TopFlash luciferase assay. Error bars are SD’s from three independent measurements (n = 3). Statistical analysis was performed with one-way ANOVA. ns, p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001. For b, p = 0.021 (HCT15; column1-2), <0.0001 (HCT15; column1-3), <0.0001 (HCT15; column1-4), 0.014 (Caco2; column1-2), <0.0001 (Caco2; column1-3), <0.0001 (Caco2; column1-4), 0.021 (DLD1; column1-2), <0.0001 (DLD1; column1-3), <0.0001 (DLD1; column1-4)., 0.68 (LOVO; column1-2), <0.0001 (LOVO; column1-3), <0.0001 (LOVO; column1-4)., 0.073 (HT29; column1-2), <0.0001 (HT29; column1-3), <0.0001 (HT29; column1-4). For c, p = 0.47 (HCT15; column1-2), <0.0001 (HCT15; column1-3), <0.0001 (HCT15; column1-4), 0.27 (Caco2; column1-2), <0.0001 (Caco2; column1-3), <0.0001 (Caco2; column1-4), 0.26 (DLD1; column1-2), <0.0001 (DLD1; column1-3), <0.0001 (DLD1; column1-4)., 0468 (LOVO; column1-2), <0.0001 (LOVO; column1-3), <0.0001 (LOVO; column1-4)., 0.28 (HT29; column1-2), <0.0001 (HT29; column1-3), <0.0001 (HT29; column1-4).
